전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved333 programs
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Autologous CD5 CAR T-cells (Autologous CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Autologous CD7 CAR T-cell (Autologous CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells (Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Autologous HuCD19 (Anti-CD19, Autologous HuCD19, Autologous HuCD19 ( Anti-CD19)CAR T cells)

Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy (Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy)

Leukemia, B-Cell · Leukemia, B-Cell

#LeukemiaB-Cell#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

BAFFR CAR-T (BAFFR CAR-T)

B Acute Lymphoblastic Leukemia/Lymphoma · B Acute Lymphoblastic Leukemia/Lymphoma

#BAcuteLymphoblasticLeukemiaLymph#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleAmgenPhase 2

Blinatumomab (BLINCYTO, BLINCYTO (Blinatumomab))

Mixed Phenotype Acute Leukemia (MPAL); Measurable Residual Disease (MRD) · Mixed Phenotype Acute Leukemia (MPAL)

#MixedPhenotypeAcuteLeukemiaMPAL#Antibody#Phase2#monoclonal-antibody#MeasurableResidualDiseaseMRD+1
Trials 1Status Active
ADCLimited DatastaleAmgenPhase 2

Blinatumomab and Inotuzumab Ozogamicin (Blinatumomab and Inotuzumab Ozogamicin)

Acute Lymphoblastic Leukemia; Immunotherapy · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#ADC#Phase2#antibody-drug-conjugate#Immunotherapy+1
Trials 1Status Recruiting
CGTLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 1

CAR-37 T cells (CAR-37 T cells)

Hematologic Malignancy; Leukemia · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleKang YUPreclinical

CAR-BCMA T cell (CAR-BCMA T cell)

B Cell Lymphoma; B Cell Leukemia · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleKang YUPreclinical

CAR-CD19 T cell (CAR-CD19 T cell)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleKang YUPreclinical

CAR-CLD18 T cell (CAR-CLD18 T cell)

B Cell Lymphoma; B Cell Leukemia · B Cell Lymphoma

#BCellLymphoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleKang YUPreclinical

CAR-GPC3 T cell (CAR-GPC3 T cell)

B Cell Lymphoma; B Cell Leukemia · B Cell Lymphoma

#BCellLymphoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleSheba Medical CenterPhase 3

CAR-T CD19 (CAR-T CD19)

Acute Myeloid Leukemia · CD19

#CD19#CGT#Phase3#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） (CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL); AML (Acute Myelogenous Leukemia) · Lymphoma, B-cell, Aggressive Non-Hodgkin

#LymphomaB-cellAggressiveNon-Hodg#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR19BCMA-T cells (CAR19BCMA-T cells)

Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 2

CAR2219-T cells (CAR2219-T cells)

Relapsed or Refractory B Cell Leukemia and Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUniversity College, LondonPhase 1

CARCCR9 T cells (CARCCR9 T cells)

T Cell Acute Lymphoblastic Leukemia; T Cell Lymphoblastic Lymphoma · T Cell Acute Lymphoblastic Leukemia

#TCellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

9 / 17 pages

← PreviousNext →